Loading…
Loading…
EQUITY / NASDAQ · XNCM
Xenetic Biosciences, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.24 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 2.24 USD · Volume 43,300
20 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Revenue | 660,601 USD | — | — |
| Operating profit | -971,690 USD | — | — |
| Net income | -929,695 USD | — | — |
| Total liabilities | 894,977 USD | — | — |
| Total equity | 6,073,021 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -929,695 USD | -1,386,077 USD | — | -456,382 USD | — | -2,680,860 USD | -509,940 USD | -2,101,784 USD |
| Operating profitIncome statement | -971,690 USD | -1,473,807 USD | — | -502,117 USD | — | -2,834,582 USD | -544,734 USD | -2,211,555 USD |
| RevenueIncome statement | 660,601 USD | 1,467,524 USD | — | 806,923 USD | — | 2,976,411 USD | 1,026,957 USD | 2,210,115 USD |
| Total assetsBalance sheet | 6,967,998 USD | — | — | 7,908,991 USD | 8,363,847 USD | 8,363,847 USD | 5,067,960 USD | — |
| Total equityBalance sheet | 6,073,021 USD | — | 6,950,752 USD | 6,950,752 USD | 7,395,822 USD | 7,395,822 USD | 3,956,185 USD | — |
| Total liabilitiesBalance sheet | 894,977 USD | — | — | 958,239 USD | 968,025 USD | 968,025 USD | 1,111,775 USD | — |
| Operating cash flowCash flow statement | — | -1,411,866 USD | — | -536,377 USD | — | -2,286,651 USD | — | -2,043,969 USD |
| Financing cash flowCash flow statement | — | — | — | — | — | 4,004,715 USD | — | — |
| Report source | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 05/12/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 03/12/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.